Clinical Trial Update: Absolute Bioavailability of BMS-791325 [Phase 1]

View source ↗

Summary

Phase 1 trial reporting the absolute bioavailability of the investigational hepatitis C drug BMS-791325.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BMS-791325

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus Infection | Phase 1 | Status: COMPLETED